Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OxyContin Ads Will Highlight Boxed Warning In Response To FDA Objection

Executive Summary

Purdue is revising its OxyContin ads to prominently feature black box warnings found in labeling following receipt of a warning letter from FDA

You may also be interested in...



Purdue Execs Plead Guilty To Misbranding OxyContin; Company Pays $700 Mil.

While other companies have been hit with heftier fines for falsely marketing their drugs, Purdue Pharma's $700.6 million agreement with the Department of Justice over OxyContin promotions has had a profound impact on the management of the company, with guilty pleas from two of the firm's top executives

Purdue Execs Plead Guilty To Misbranding OxyContin; Company Pays $700 Mil.

While other companies have been hit with heftier fines for falsely marketing their drugs, Purdue Pharma's $700.6 million agreement with the Department of Justice over OxyContin promotions has had a profound impact on the management of the company, with guilty pleas from two of the firm's top executives

FDA Preclearance Of DTC Ads Included In Sen. Kennedy Draft Bill

Repeat offenders of direct-to-consumer advertising regulations would be required to submit all future ads to FDA for preclearance under a draft bill sponsored by Sen. Edward Kennedy (D-Mass.)

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS041164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel